Related Experiment Videos
Factors Contributing to Non-Initiation of Planned Systemic Therapy Among Inpatients Evaluated for a Phase II
Kolton Kardokus1, Cameron Anzel1, Momina Anwar2
1Department of Medicine.
Objectives:
The Spine Patient Optimal Radiosurgery Treatment for Symptomatic MEtastatic Neoplasms (SPORTSMEN) multicenter phase II randomized controlled trial evaluates radiation therapy (RT) for symptomatic spinal metastases, with 3-month pain-relief as the primary endpoint. The Inpatient Metastatic Spine Score (IMSS) identifies inpatients with anticipated survival to meet this endpoint. Because systemic therapy eligibility is an IMSS component and contributes to survival, understanding the reversal of intended systemic treatment may refine RT patient selection.
Methods:
Inpatients at an NCI-designated cancer center evaluated for SPORTSMEN with planned but uninitiated systemic therapy were retrospectively evaluated. Clinical characteristics, trial status, RT, functional status, hospitalization events, IMSS, and treatment decisions were abstracted from the EMR. Oncology documentation and goals-of-care discussions identified treatment plan changes.
Results:
Three patients were identified. All met the SPORTSMEN eligibility criteria and had medical oncology plans for systemic therapy. Baseline ECOG ranged from 1 to 3. Performance status decline following evaluation (median of 5 d) and goals-of-care changes drove treatment noninitiation. Median time from systemic therapy support to noninitiation was 6 days, and median time from trial evaluation to transition in care goals was 10 days; 2 patients transitioned to hospice and 1 to palliative-intent care. Two patients would not have qualified for enrollment by IMSS if the initial treatment plan withheld systemic therapy.
Conclusions:
Among inpatients evaluated for SPORTSMEN, reversal of planned systemic therapy occurred over 6 days. This timeframe should inform evaluation for trial enrollment with regard to overall prognosis. Longitudinal functional assessment and early goals-of-care discussions with validated prognostic tools may improve identification of patients likely to benefit from RT.
Related Concept Videos
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Clinical Trials
There are four phases in a clinical trial. A phase one...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials: Overview
Factors Affecting Drug Response: Overview